MSU research develops precision nanoparticle therapy to combat heart disease

Michigan State University researchers have developed a cutting-edge nanotherapy that could change how we treat cardiovascular disease, which also happens to be the leading cause of death in the U.S. The new approach, led by Bryan Smith and his team, focuses on combating artery inflammation — a key driver of heart disease.

Their treatment uses nanoparticles, materials smaller than a human hair, to target immune cells responsible for arterial plaque buildup. By doing so, the nanotherapy stimulates them to "eat away" parts of the plaque core, which further reduces inflammation in the arteries and lowers the risk of heart attacks.

The team successfully tested the infusion on pig models, showing reduced artery inflammation without side effects. This in itself is a major achievement for future human trials, bringing us one step closer to safer, more precise cardiovascular therapies. Treating highly inflammatory plaque is key - it can rupture without warning, causing sudden and severe heart attacks. As Smith explained, this type of plaque poses a greater threat because it may not cause visible blockages but can lead to fatal consequences.

With the therapy now produced at volumes suitable for human use, clinical trials may not be far off. The detailed study is available here.